Savior Lifetec Corporation (TPEX:4167)

Market Cap	5.54B
Revenue (ttm)	1.21B
Net Income (ttm)	458.56M
Shares Out	317.40M
EPS (ttm)	1.45
PE Ratio	12.06
Forward PE	n/a
Dividend	0.09 (0.49%)
Ex-Dividend Date	Jul 14, 2025

Volume	2,107,107
Average Volume	574,930
Open	17.15
Previous Close	17.60
Day's Range	16.85 - 17.50
52-Week Range	14.35 - 23.70
Beta	0.32
RSI	32.07
Earnings Date	Aug 8, 2025

About Savior Lifetec

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, meropenem, and ertapenem products. The company was founded in 1993 and is headquartered in Miaoli County, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 384
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4167

Financial Performance

In 2024, Savior Lifetec's revenue was 1.22 billion, an increase of 15.91% compared to the previous year's 1.05 billion. Earnings were 182.38 million, an increase of 507.33%.